Healthineers Is Paying €300 Million to Become Smaller
A flat EPS guide, three exits on one timeline, and the innovation story quietly demoted to a footnote
SHL.DE · Earnings Call · 2026-11-05
The quarter was fine. The company is being taken apart.
Siemens Healthineers closed fiscal 2026 with what the CEO called "a strong quarter": group revenue up 5.9%, the synergetic core up 8.1%, equipment book-to-bill of 1.15 in Q4 and 1.14 for the year, adjusted EPS of €2.42 and a flat €1 dividend. On the surface, a compounder doing compounder things. Then you strip out the €0.16 of tariff refunds and the Q4 one-offs, and the clean base is €2.30 — precisely the midpoint of the original guidance range. Fiscal 2027 is guided at €2.20 to €2.40. Midpoint: €2.30. Two consecutive years of zero adjusted EPS growth, inside a company that opened the call reconfirming double-digit adjusted EPS growth as its medium-term target. Everything heroic has been pushed past 2027. What actually changed this quarter is corporate structure, and the keyword set says it bluntly. Siemens AG is now the single highest-momentum term in the transcript, alongside deconsolidation from Siemens, stranded costs and a new Transform4Future productivity program. For a decade this franchise sold innovation; this quarter it sold plumbing.Three exits, one timeline
The February shareholder votes will trigger the spin-off from Siemens AG. Diagnostics gets a new name — Olyrian Diagnostics — and its own P&L, with a carve-out running to mid-2028: “The carve-out has been initiated with a clear intention to separate creating the foundation for Diagnostics to transition to a fully stand-alone company by mid of calendar year 2028.” — Bernhard Montag, CEO · 2026-11-05 And the ultrasound equipment business is simply being killed. Not sold, not spun — wound down:The arithmetic: ultrasound is roughly €600m of a €12bn base, more than half of it procedural; about €200m of General Imaging systems and service disappears, costing 0.7 points of growth and roughly €50m (€0.03 EPS) of stranded cost. Add the separation and the Diagnostics carve-out and management flags over €300m of costs to be offset by Transform4Future — a program whose P&L benefit only begins in fiscal 2028: “These costs amount to over EUR 300 million over time, which we will mitigate with the productivity program, Transform4Future.” — Jochen Schmitz, CFO · 2026-11-05 There is also a €300m brand fee to Siemens, paid in three €100m instalments over 36 months, carved out of adjusted EPS. And €600m of fresh adjustments in FY27 alone for legal, refinancing, IT verticalisation and the brand transition. This is a company paying real cash to become smaller.Falko, thanks for the question. We will just wind it down, so to say, we won't sell it.
The themes management quietly stopped talking about
The most revealing thing in the keyword history is what vanished. In the prior quarter, tariff refund was the company's number-one keyword; today it is nowhere in the top 30, notwithstanding that €0.16 of the year's EPS came from exactly that. The tariff narrative that dominated four consecutive quarters of these calls — mitigation, smart pricing, value-add shifts — has been absorbed into the base and demoted to a footnote. That is partly maturity and partly convenience: a refund is not a strategy. More striking: photon counting CT, the company's flagship innovation proof point and a top-five keyword as recently as last quarter, has also fallen out of the curated set entirely. So has central bidding, the China go-to-market storyline that ran through 2026. The innovation case — the €1bn radiopharma business, PETNET, dual-source CT, the theranostics debate — got perhaps ten minutes of airtime, mostly in answer to one analyst question about vertical integration, which management politely declined. Meanwhile Central Items — the accounting bucket where the general imaging service business is being parked — keeps reappearing across the years like a bad penny. Structure is the story now.Prudence has become the product
Analysts noticed the change in guidance-setting behaviour, and the CFO did not deny it:The evidence for that prudence is easy to assemble. Book-to-bill is at record levels, yet Imaging is guided to decent mid-single digit growth against a 6-9% midterm ambition, and Hassan Al-Wakeel asked the obvious question — “Why you're not expecting a stronger top line in 2027, even adjusting for the ultrasound dilution.” — Hassan Al-Wakeel, Analyst · 2026-11-05 The answer was China: a slight decline assumed in the synergetic core, plus a Diagnostics business whose China revenue fell over 30% last year and is now only around 7% of the division. The new product is deliberately excluded from the numbers. Accela — 97 seconds of beam-on time for a case previously untreatable — launched at ASTRO five weeks ago, with European approval and first patients expected before year-end. The CFO's view: “it's a bit too early to expect this in 2027.” — Jochen Schmitz, CFO · 2026-11-05 Optionality banked for 2028. Worth remembering how this story surfaced. In February, the CEO was asked about Diagnostics commitment and said “there is, of course, optionality in the long run, whether we are the better owner or not.” — Bernhard Montag, Chief Executive Officer · 2026-02-05 Nine months later the carve-out exists. That is a company telegraphing its moves one call ahead — useful, and also a reminder that the mid-teens Diagnostics margin ambition, reiterated again today, has now been confirmed for at least four consecutive quarters while the division's margin printed around 4% normalized.I would say, your initial assumption that this is a more prudent guide than in most of the recent past. I would concur with that statement.